VAC 18193 Market Size, Forecast, and Emerging Insight - 2032

“VAC 18193 Market Size, Forecast, and Emerging Insight - 2032” report provides comprehensive insights about VAC 18193 for Respiratory syncytial virus (RSV) in the seven major markets. A detailed picture of the VAC 18193 for RSV in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the VAC 18193 for RSV. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the VAC 18193 market forecast analysis for RSV in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in RSV.

Drug Summary

VAC 18193 is Janssen’s investigational prophylactic RSV senior vaccine, which is being investigated to prevent RSV-mediated lower respiratory tract disease in adults aged 60 or older. The prophylactic RSV senior vaccine candidate leverages unique features of Janssen’s adenovector platform (AdVac). The investigational vaccine contains the gene encoding for the fusion protein of the RSV virus as an antigen.

The Company has planned submissions in US and Europe in 2022 for RSV in adult’s patients.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the VAC 18193 description, mechanism of action, dosage and administration, research and development activities in Respiratory syncytial virus (RSV).
• Elaborated details on VAC 18193 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the VAC 18193 research and development activities in RSV across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around VAC 18193.
• The report contains forecasted sales of VAC 18193 for RSV till 2032.
• Comprehensive coverage of the late-stage emerging therapies for RSV.
• The report also features the SWOT analysis with analyst views for VAC 18193 in RSV.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the publisher’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

VAC 18193 Analytical Perspective

In-depth VAC 18193 Market Assessment

This report provides a detailed market assessment of VAC 18193 for Respiratory syncytial virus (RSV) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

VAC 18193 Clinical Assessment

The report provides the clinical trials information of VAC 18193 for RSV covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Respiratory syncytial virus (RSV) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence VAC 18193 dominance.
• Other emerging products for RSV are expected to give tough market competition to VAC 18193 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of VAC 18193 in RSV.
• Our in-depth analysis of the forecasted sales data of VAC 18193 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the VAC 18193 in RSV.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of VAC 18193?
• What is the clinical trial status of the study related to VAC 18193 in Respiratory syncytial virus (RSV) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the VAC 18193 development?
• What are the key designations that have been granted to VAC 18193 for RSV?
• What is the forecasted market scenario of VAC 18193 for RSV?
• What are the forecasted sales of VAC 18193 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to VAC 18193 for RSV?
• Which are the late-stage emerging therapies under development for the treatment of RSV?

This product will be delivered within 2 business days.